Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Return on Capital Employed (2022 - 2025)

Stoke Therapeutics has reported Return on Capital Employed over the past 4 years, most recently at 6.21% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 3561.0% year-over-year to 6.21%; the TTM value through Dec 2025 reached 6.21%, up 3561.0%, while the annual FY2025 figure was 7.17%, 4113.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 6.21% at Stoke Therapeutics, down from 8.22% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 12.98% in Q1 2025 and troughed at 65.38% in Q1 2024.
  • A 4-year average of 32.47% and a median of 44.32% in 2022 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: tumbled -2147bps in 2024 and later surged 7837bps in 2025.
  • Year by year, Return on Capital Employed stood at 44.32% in 2022, then decreased by -27bps to 56.46% in 2023, then rose by 26bps to 41.82% in 2024, then surged by 85bps to 6.21% in 2025.
  • Business Quant data shows Return on Capital Employed for STOK at 6.21% in Q4 2025, 8.22% in Q3 2025, and 11.28% in Q2 2025.